1. Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1 infection. Issue 10 (12th June 2016) Authors: Gane, E.; Ben Ari, Z.; Mollison, L.; Zuckerman, E.; Bruck, R.; Baruch, Y.; Howe, A. Y. M.; Wahl, J.; Bhanja, S.; Hwang, P.; Zhao, Y.; Robertson, M. N. Journal: Journal of viral hepatitis Issue: Volume 23:Issue 10(2016) Page Start: 789 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗